Non-genomic actions of the androgen receptor in prostate cancer

Frontiers in Endocrinology

Volumn 8, Issue JAN, 2017, Pages

  Leung, Jacky K ^a   Sadar, Marianne D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Androgen receptor; AR antagonists; MAPK ERK signaling; Non genomic signaling; PI3K Akt signaling; Prostate cancer; Src kinase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; CHAPERONE; DASATINIB; EPI 506; GALETERONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NICLOSAMIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; SARACATINIB; SINTOKAMIDE A; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL MIGRATION; CELL PROLIFERATION; CYTOPLASM; GENE EXPRESSION; HUMAN; LIGAND BINDING; LNCAP CELL LINE; MOLECULAR INTERACTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SHORT SURVEY; SIGNAL TRANSDUCTION;

EID: 85011931530     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2017.0002     Document Type: Short Survey

References (85)

1. Golabek T, Belsey J, Drewa T, Kolodziej A, Skoneczna I, Milecki P, et al. Evidence-based recommendations on androgen deprivation therapy for localized and advanced prostate cancer. Cent European J Urol (2016) 69(2):131-8. doi:10.5173/ceju.2016.812.
2. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol (2015) 16(2):152-60. doi:10.1016/S1470-2045(14)71205-7.
3. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol (2016) 71(2):151-4. doi:10.1016/j.eururo.2016.07.032.
4. Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol (2015) 67(3):470-9. doi:10.1016/j.eururo.2014.09.049.
5. Imamura Y, Sadar MD. Androgen receptor targeted therapies in castration-resistant prostate cancer: bench to clinic. Int J Urol (2016) 23(8):654-65. doi:10.1111/iju.13137.
6. Sadar MD. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J Biol Chem (1999) 274(12):7777-83. doi:10.1074/jbc.274.12.7777.
7. Ueda T, Bruchovsky N, Sadar MD. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. J Biol Chem (2002) 277(9):7076-85. doi:10.1074/jbc.M108255200.
8. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY, et al. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem (2003) 278(51):50902-7. doi:10.1074/jbc.M300676200.
9. Gregory CW, Fei X, Ponguta LA, He B, Bill HM, French FS, et al. Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J Biol Chem (2004) 279(8):7119-30. doi:10.1074/jbc.M307649200.
10. Wen Y, Hu MC, Makino K, Spohn B, Bartholomeusz G, Yan DH, et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res (2000) 60(24):6841-5.
11. Nazareth LV, Weigel NL. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem (1996) 271(33):19900-7. doi:10.1074/jbc.271.33.19900.
12. Jenster G, van der Korput JA, Trapman J, Brinkmann AO. Functional domains of the human androgen receptor. J Steroid Biochem Mol Biol (1992) 41(3-8):671-5. doi:10.1016/0960-0760(92)90402-5.
13. Chamberlain NL, Whitacre DC, Miesfeld RL. Delineation of two distinct type 1 activation functions in the androgen receptor amino-terminal domain. J Biol Chem (1996) 271(43):26772-8. doi:10.1074/jbc.271.43.26772.
14. Smith DF, Toft DO. Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. Mol Endocrinol (2008) 22(10):2229-40. doi:10.1210/me.2008-0089.
15. Ozanne DM, Brady ME, Cook S, Gaughan L, Neal DE, Robson CN. Androgen receptor nuclear translocation is facilitated by the f-actin cross-linking protein filamin. Mol Endocrinol (2000) 14(10):1618-26. doi:10.1210/mend.14.10.0541.
16. Loy CJ, Sim KS, Yong EL. Filamin-A fragment localizes to the nucleus to regulate androgen receptor and coactivator functions. Proc Natl Acad Sci U S A (2003) 100(8):4562-7. doi:10.1073/pnas.0736237100.
17. Migliaccio A, Castoria G, Di Domenico M, de Falco A, Bilancio A, Lombardi M, et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO J (2000) 19(20):5406-17. doi:10.1093/emboj/19.20.5406.
18. Zarif JC, Lamb LE, Schulz VV, Nollet EA, Miranti CK. Androgen receptor non-nuclear regulation of prostate cancer cell invasion mediated by Src and matriptase. Oncotarget (2015) 6(9):6862-76. doi:10.18632/oncotarget.3119.
19. Migliaccio A, Varricchio L, De Falco A, Castoria G, Arra C, Yamaguchi H, et al. Inhibition of the SH3 domain-mediated binding of Src to the androgen receptor and its effect on tumor growth. Oncogene (2007) 26(46):6619-29. doi:10.1038/sj.onc.1210487.
20. Unni E, Sun S, Nan B, McPhaul MJ, Cheskis B, Mancini MA, et al. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence. Cancer Res (2004) 64(19):7156-68. doi:10.1158/0008-5472.CAN-04-1121.
21. Berns EM, de Boer W, Mulder E. Androgen-dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate (1986) 9(3):247-59. doi:10.1002/pros.2990090305.
22. Olea N, Sakabe K, Soto AM, Sonnenschein C. The proliferative effect of "anti-androgens" on the androgen-sensitive human prostate tumor cell line LNCaP. Endocrinology (1990) 126(3):1457-63. doi:10.1210/endo-126-3-1457.
23. de Launoit Y, Veilleux R, Dufour M, Simard J, Labrie F. Characteristics of the biphasic action of androgens and of the potent antiproliferative effects of the new pure antiestrogen EM-139 on cell cycle kinetic parameters in LNCaP human prostatic cancer cells. Cancer Res (1991) 51(19):5165-70.
24. Castoria G, Lombardi M, Barone MV, Bilancio A, Di Domenico M, Bottero D, et al. Androgen-stimulated DNA synthesis and cytoskeletal changes in fibroblasts by a nontranscriptional receptor action. J Cell Biol (2003) 161(3):547-56. doi:10.1083/jcb.200211099.
25. Castoria G, D'Amato L, Ciociola A, Giovannelli P, Giraldi T, Sepe L, et al. Androgen-induced cell migration: role of androgen receptor/filamin A association. PLoS One (2011) 6(2):e17218. doi:10.1371/journal.pone.0017218.
26. Castoria G, Giovannelli P, Di Donato M, Ciociola A, Hayashi R, Bernal F, et al. Role of non-genomic androgen signalling in suppressing proliferation of fibroblasts and fibrosarcoma cells. Cell Death Dis (2014) 5:e1548. doi:10.1038/cddis.2014.497.
27. Bedolla RG, Wang Y, Asuncion A, Chamie K, Siddiqui S, Mudryj MM, et al. Nuclear versus cytoplasmic localization of filamin A in prostate cancer: immunohistochemical correlation with metastases. Clin Cancer Res (2009) 15(3):788-96. doi:10.1158/1078-0432.CCR-08-1402.
28. Ghosh PM, Malik SN, Bedolla RG, Wang Y, Mikhailova M, Prihoda TJ, et al. Signal transduction pathways in androgen-dependent and-independent prostate cancer cell proliferation. Endocr Relat Cancer (2005) 12(1):119-34. doi:10.1677/erc.1.00835.
29. Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene (1999) 18(46):6322-9. doi:10.1038/sj.onc.1203032.
30. Yang SH, Yates PR, Whitmarsh AJ, Davis RJ, Sharrocks AD. The Elk-1 ETS-domain transcription factor contains a mitogen-activated protein kinase targeting motif. Mol Cell Biol (1998) 18(2):710-20. doi:10.1128/MCB.18.2.710.
31. Marais R, Wynne J, Treisman R. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell (1993) 73(2):381-93. doi:10.1016/0092-8674(93)90237-K.
32. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and-independent mechanisms. Science (1999) 286(5443):1358-62. doi:10.1126/science.286.5443.1358.
33. Gelman IH. Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinases. Int J Biol Sci (2014) 10(6):620-6. doi:10.7150/ijbs.8264.
34. Posadas EM, Al-Ahmadie H, Robinson VL, Jagadeeswaran R, Otto K, Kasza KE, et al. FYN is overexpressed in human prostate cancer. BJU Int (2009) 103(2):171-7. doi:10.1111/j.1464-410X.2008.08009.x.
35. Zardan A, Nip KM, Thaper D, Toren P, Vahid S, Beraldi E, et al. Lyn tyrosine kinase regulates androgen receptor expression and activity in castrate-resistant prostate cancer. Oncogenesis (2014) 3:e115. doi:10.1038/oncsis.2014.30.
36. Asim M, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene (2008) 27(25):3596-604. doi:10.1038/sj.onc.1211016.
37. Varkaris A, Katsiampoura AD, Araujo JC, Gallick GE, Corn PG. Src signaling pathways in prostate cancer. Cancer Metastasis Rev (2014) 33(2-3):595-606. doi:10.1007/s10555-013-9481-1.
38. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 65(20):9185-9. doi:10.1158/0008-5472.CAN-05-1731.
39. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem (2004) 47(27):6658-61. doi:10.1021/jm049486a.
40. Recchia I, Rucci N, Festuccia C, Bologna M, MacKay AR, Migliaccio S, et al. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer (2003) 39(13):1927-35. doi:10.1016/S0959-8049(03)00394-0.
41. Baron S, Manin M, Beaudoin C, Leotoing L, Communal Y, Veyssiere G, et al. Androgen receptor mediates non-genomic activation of phosphatidylinositol 3-OH kinase in androgen-sensitive epithelial cells. J Biol Chem (2004) 279(15):14579-86. doi:10.1074/jbc.M306143200.
42. Yang L, Xie S, Jamaluddin MS, Altuwaijri S, Ni J, Kim E, et al. Induction of androgen receptor expression by phosphatidylinositol 3-kinase/Akt downstream substrate, FOXO3a, and their roles in apoptosis of LNCaP prostate cancer cells. J Biol Chem (2005) 280(39):33558-65. doi:10.1074/jbc.M504461200.
43. Liu P, Li S, Gan L, Kao TP, Huang H. A transcription-independent function of FOXO1 in inhibition of androgen-independent activation of the androgen receptor in prostate cancer cells. Cancer Res (2008) 68(24):10290-9. doi:10.1158/0008-5472.CAN-08-2038.
44. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 18(1):11-22. doi:10.1016/j.ccr.2010.05.026.
45. Gioeli D, Paschal BM. Post-translational modification of the androgen receptor. Mol Cell Endocrinol (2012) 352(1-2):70-8. doi:10.1016/j.mce.2011.07.004.
46. Mahajan NP, Liu Y, Majumder S, Warren MR, Parker CE, Mohler JL, et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A (2007) 104(20):8438-43. doi:10.1073/pnas.0700420104.
47. Guo Z, Dai B, Jiang T, Xu K, Xie Y, Kim O, et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell (2006) 10(4):309-19. doi:10.1016/j.ccr.2006.08.021.
48. DaSilva J, Gioeli D, Weber MJ, Parsons SJ. The neuroendocrine-derived peptide parathyroid hormone-related protein promotes prostate cancer cell growth by stabilizing the androgen receptor. Cancer Res (2009) 69(18):7402-11. doi:10.1158/0008-5472.CAN-08-4687.
49. Blaszczyk N, Masri BA, Mawji NR, Ueda T, McAlinden G, Duncan CP, et al. Osteoblast-derived factors induce androgen-independent proliferation and expression of prostate-specific antigen in human prostate cancer cells. Clin Cancer Res (2004) 10(5):1860-9. doi:10.1158/1078-0432.CCR-0974-3.
50. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, et al. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene (2004) 23(12):2197-205. doi:10.1038/sj.onc.1207344.
51. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene (2007) 26(22):3291-310. doi:10.1038/sj.onc.1210422.
52. Ponguta LA, Gregory CW, French FS, Wilson EM. Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer. J Biol Chem (2008) 283(30):20989-1001. doi:10.1074/jbc.M802392200.
53. Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R. Stat3 activation by Src induces specific gene regulation and is required for cell transformation. Mol Cell Biol (1998) 18(5):2545-52. doi:10.1128/MCB.18.5.2545.
54. Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, et al. Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene (2001) 20(20):2499-513. doi:10.1038/sj.onc.1204349.
55. Ueda T, Mawji NR, Bruchovsky N, Sadar MD. Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. J Biol Chem (2002) 277(41):38087-94. doi:10.1074/jbc.M203313200.
56. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc Natl Acad Sci U S A (2001) 98(13):7200-5. doi:10.1073/pnas.121173298.
57. Gomella LG. Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev Urol (2009) 11(2):52-60.
58. Heyns CF, Simonin MP, Grosgurin P, Schall R, Porchet HC; South African Triptorelin Study G. Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer. BJU Int (2003) 92(3):226-31. doi:10.1046/j.1464-410X.2003.04308.x.
59. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res (2004) 10(2):440-8. doi:10.1158/1078-0432.CCR-1146-03.
60. Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, et al. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. Eur Urol (2015) 67(1):53-60. doi:10.1016/j.eururo.2014.05.005.
61. Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 72(6):1494-503. doi:10.1158/0008-5472.CAN-11-3948.
62. Fizazi K, Massard C, Bono P, Jones R, Kataja V, James N, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol (2014) 15(9):975-85. doi:10.1016/S1470-2045(14)70240-2.
63. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 19(5):575-86. doi:10.1016/j.ccr.2011.04.008.
64. Sun S, Sprenger CC, Vessella RL, Haugk K, Soriano K, Mostaghel EA, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 120(8):2715-30. doi:10.1172/JCI41824.
65. Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 69(6):2305-13. doi:10.1158/0008-5472.CAN-08-3795.
66. Pandini G, Mineo R, Frasca F, Roberts CT Jr, Marcelli M, Vigneri R, et al. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells. Cancer Res (2005) 65(5):1849-57. doi:10.1158/0008-5472.CAN-04-1837.
67. Yang X, Guo Z, Sun F, Li W, Alfano A, Shimelis H, et al. Novel membrane-associated androgen receptor splice variant potentiates proliferative and survival responses in prostate cancer cells. J Biol Chem (2011) 286(41):36152-60. doi:10.1074/jbc.M111.265124.
68. Jagla M, Feve M, Kessler P, Lapouge G, Erdmann E, Serra S, et al. A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology (2007) 148(9):4334-43. doi:10.1210/en.2007-0446.
69. Andersen RJ, Mawji NR, Wang J, Wang G, Haile S, Myung JK, et al. Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 17(6):535-46. doi:10.1016/j.ccr.2010.04.027.
70. Banuelos CA, Tavakoli I, Tien AH, Caley DP, Mawji NR, Li Z, et al. Sintokamide A is a novel antagonist of androgen receptor that uniquely binds activation function-1 in its amino-terminal domain. J Biol Chem (2016) 291(42):22231-43. doi:10.1074/jbc.M116.734475.
71. Yang YC, Banuelos CA, Mawji NR, Wang J, Kato M, Haile S, et al. Targeting androgen receptor activation function-1 with EPI to overcome resistance mechanisms in castration-resistant prostate cancer. Clin Cancer Res (2016) 22(17):4466-77. doi:10.1158/1078-0432.CCR-15-2901.
72. De Mol E, Fenwick RB, Phang CT, Buzon V, Szulc E, de la Fuente A, et al. EPI-001, A compound active against castration-resistant prostate cancer, targets transactivation unit 5 of the androgen receptor. ACS Chem Biol (2016) 11(9):2499-505. doi:10.1021/acschembio.6b00182.
73. Yu Z, Cai C, Gao S, Simon NI, Shen HC, Balk SP. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res (2014) 20(15):4075-85. doi:10.1158/1078-0432.CCR-14-0292.
74. Purushottamachar P, Godbole AM, Gediya LK, Martin MS, Vasaitis TS, Kwegyir-Afful AK, et al. Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer. J Med Chem (2013) 56(12):4880-98. doi:10.1021/jm400048v.
75. Liu C, Lou W, Zhu Y, Nadiminty N, Schwartz CT, Evans CP, et al. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer. Clin Cancer Res (2014) 20(12):3198-210. doi:10.1158/1078-0432.CCR-13-3296.
76. Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, et al. Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687. J Nucl Med (2015) 56(3):354-60. doi:10.2967/jnumed.114.146936.
77. Araujo JC, Trudel GC, Saad F, Armstrong AJ, Yu EY, Bellmunt J, et al. Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncol (2013) 14(13):1307-16. doi:10.1016/S1470-2045(13)70479-0.
78. Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL III, et al. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: a University of Chicago phase 2 consortium and DOD/PCF prostate cancer clinical trials consortium study. Prostate (2016) 76(3):286-93. doi:10.1002/pros.23119.
79. Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, et al. A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol (2013) 71(4):883-92. doi:10.1007/s00280-013-2079-z.
80. Bitting RL, Armstrong AJ. Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer. Endocr Relat Cancer (2013) 20(3):R83-99. doi:10.1530/ERC-12-0394.
81. Statz CM, Patterson SE, Mockus SM. mTOR inhibitors in castration-resistant prostate cancer: a systematic review. Target Oncol (2016). doi:10.1007/s11523-016-0453-6.
82. Toren P, Kim S, Cordonnier T, Crafter C, Davies BR, Fazli L, et al. Combination AZD5363 with enzalutamide significantly delays enzalutamide-resistant prostate cancer in preclinical models. Eur Urol (2015) 67(6):986-90. doi:10.1016/j.eururo.2014.08.006.
83. Ramamurthy VP, Ramalingam S, Gediya L, Kwegyir-Afful AK, Njar VC. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines. Oncotarget (2015) 6(5):3195-210. doi:10.18632/oncotarget.3084.
84. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res (2009) 15(15):4799-805. doi:10.1158/1078-0432.CCR-08-0125.
85. Kato M, Banuelos CA, Imamura Y, Leung JK, Caley DP, Wang J, et al. Cotargeting androgen receptor splice variants and mTOR signaling pathway for the treatment of castration-resistant prostate cancer. Clin Cancer Res (2016) 22(11):2744-54. doi:10.1158/1078-0432.CCR-15-2119.